Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
US6579857B1 · kind B1 · utility
25Cited by
27References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 11, 1999 |
| Grant date | Jun 17, 2003 |
| Priority date | — |
| Expiry date | Jun 11, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/70
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides materials and methods for the treatment of neoplastic disease states, especially cancers of cells/organs of epithelial origin. For example, the invention provides combination chemotherapy materials and methods for treatment comprising a first agent comprising adenosine or an adenosine derivative and a second agent comprising an inhibitor of at least one of the enzymes adenosine deaminase and AMP deaminase.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.